Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma

被引：0
|
作者：
Sievert, W. [1 ,2 ]
Strasser, S. [3 ]
Gane, E. [4 ]
George, J. [5 ]
Weilert, F. [6 ]
Flaherty, J. F. [7 ]
Dinh, P. [7 ]
Schall, R. A. [7 ]
Martins, E. B. [7 ]
Yee, L. [7 ]
Marcellin, P. [8 ]
Kim, W. R. [9 ]
机构：
[1] Monash Univ, Melbourne, Vic 3004, Australia
[2] Monash Med Ctr, Melbourne, Vic, Australia
[3] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[4] Auckland City Hosp, Auckland, New Zealand
[5] Univ Sydney, Westmead Hosp, Storr Liver Unit, Sydney, NSW 2006, Australia
[6] Waikato Hosp, Hamilton, New Zealand
[7] Gilead Sci Inc, Foster City, CA 94404 USA
[8] Hop Beaujon, Clichy, France
[9] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：53 / 54
页数：2
相关论文
共 50 条
  • [21] Quantitative collagen and liver fibrosis by morphometric assessment in chronic hepatitis B patients treated with long term tenofovir disoproxil fumarate (TDF)
    Chan, Alain
    Goodman, Zachary
    Afdhal, Nezam
    Buti, Maria
    Gane, Edward
    Krastev, Zachary
    Alaparthi, Lakshmi
    Monge, Fanny
    Schall, Raul Aguilar
    Kim, Sun Sook
    Bornstein, Jeffrey
    Mchutchison, John
    Dusheiko, Geoffrey
    Kaita, Kelly
    Manns, Michael
    Marcellin, Patrick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 184 - 184
  • [22] Tenofovir disoproxil fumarate is not associated with a lower risk of hepatocellular carcinoma compared to entecavir in patients with chronic hepatitis B
    Lee, Hye Won
    Kim, Seung Up
    HEPATOMA RESEARCH, 2022, 8
  • [23] Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir
    Lim, Jung Hyun
    Yu, Jung Hwan
    Suh, Young Ju
    Lee, Jin-Woo
    Jin, Young-Joo
    MEDICINE, 2021, 100 (39) : E27417
  • [24] Safety of tenofovir alafenamide (TAF) in patients with a history of proximal renal tubulopathy on tenofovir disoproxil fumarate (TDF)
    Hamzah, L.
    Jones, R.
    Bailey, A.
    Williams, D.
    Johnson, M.
    Ibrahim, F.
    Musso, C.
    Burling, K.
    Campbell, L.
    Post, F.
    HIV MEDICINE, 2019, 20 : 8 - 9
  • [25] Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver Disease
    Liaw, Yun-Fan
    Sheen, I-Shyan
    Lee, Chuan-Mo
    Akarca, Ulus Salih
    Papatheodoridis, George V.
    Wong, Florence Suet-Hing
    Chang, Ting-Tsung
    Horban, Andrzej
    Wang, Chia
    Kwan, Peter
    Buti, Maria
    Prieto, Martin
    Berg, Thomas
    Kitrinos, Kathryn
    Peschell, Ken
    Mondou, Elsa
    Frederick, David
    Rousseau, Franck
    Schiff, Eugene R.
    HEPATOLOGY, 2011, 53 (01) : 62 - 72
  • [26] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
    Pan, Calvin Q.
    Gane, Edward
    Seto, Wai-Kay
    Janssen, Harry L.
    Caruntu, Florin
    Kim, Hyung Joon
    Abdurakhmanov, Dzhamal
    Nishiguchi, Shuhei
    Bae, Ho
    Mo, Shuyuan
    Suri, Vithika
    Gaggar, Anuj
    Flaherty, John F.
    Kao, Jia-Horng
    Brunetto, Maurizia Rossana
    Buti, Maria
    GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
  • [27] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use
    Gane, E.
    Seto, W. K.
    Janssen, H.
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Andrzej, H.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J. F.
    Kao, J-H
    Brunetto, M.
    Buti Ferret, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 42 - 43
  • [28] SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE
    Buti, Maria
    Lampertico, Pietro
    Lim, Young-Suk
    Agarwal, Kosh
    Fung, Scott K.
    Tsang, Owen
    Elkhashab, Magdy
    Kao, Jia-Horng
    Luis Calleja, Jose
    Khalili, Mandana
    Ravendhran, Natarajan
    Tan, Susanna
    Flaherty, John F.
    Gaggar, Anuj
    Lau, Audrey H.
    Wu, George
    Hann, Hie-Won L.
    Pan, Calvin
    Kim, Hyung Joon
    Kennedy, Patrick T. F.
    Chan, Henry Lik Yuen
    HEPATOLOGY, 2019, 70 : 301A - 301A
  • [29] COMPARATIVE ANALYSIS OF HEPATOCELLULAR CARCINOMA RISK IN CHRONIC HEPATITIS B PATIENTS TREATED WITH TENOFOVIR ALAFENAMIDE ( TAF), TENOFOVIR DISOPROXIL FUMARATE ( TDF), AND ENTECAVIR ( ETV): A SYSTEMATIC REVIEW AND META- ANALYSIS WITH GRADE ASSESSMENT
    Polpichai, Natchaya
    Saowapa, Sakditad
    Jaroenlapnopparat, Aunchalee
    Wattanachayakul, Phuuwadith
    Danpanichkul, Pojsakorn
    Trongtorsak, Angkawipa
    Sripongpun, Pimsiri Sripongpun
    Chamroonkul, Naichaya
    Tangkijvanich, Pisit
    Liangpunsakul, Suthat
    Piratvisuth, Teerha
    Kaewdech, Apichat
    HEPATOLOGY, 2024, 80 : S191 - S193
  • [30] From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B
    Rodrigo, Minna
    Hartley, Christopher
    Wasuwanich, Paul
    Van, Trung
    Karnsakul, Wikrom
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (12) : 1099 - 1106
12345